This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Should You Continue to Retain LH Stock in Your Portfolio?
by Zacks Equity Research
Labcorp's expanding testing solutions in high-growth areas, partnerships and focus on operational efficiency instill optimism.
LH Stock Likely to Gain From the Molecular Bioanalytical Lab Expansion
by Zacks Equity Research
Labcorp expands the molecular bioanalytical laboratory in Greenfield, IN.
Labcorp Stock Gains From Its Latest Acquisition of BioReference Health
by Zacks Equity Research
LH completes the acquisition of BioReference Health, a wholly-owned subsidiary of OPKO Health. The acquisition includes BioReference Health's laboratory testing businesses.
Labcorp Stock Gains From Market Expansion Efforts Amid Macro Woes
by Zacks Equity Research
LH is well-placed for long-term success in Cell & Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business.
LH Stock Expected to Gain From the Ballad Health Acquisition Deal
by Zacks Equity Research
Labcorp has reached an agreement to purchase select outreach laboratory services from Ballad Health.
Should You Hold Labcorp (LH) Stock in Your Portfolio Now?
by Zacks Equity Research
Labcorp's (LH) slew of partnerships and acquisitions and robust efforts in high-growth areas bode well.
Labcorp (LH) Gains From New Collaborations Amid FX Issues
by Zacks Equity Research
Labcorp's (LH) Biopharma Laboratory Services business is benefiting from collaborations with leading pharmaceutical and biotechnology companies.
Labcorp (LH) Q2 Earnings Surpass Estimates (revised)
by Mark Vickery
Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.
Labcorp (LH) Q2 Earnings Surpass Estimates, Margins Increase
by Zacks Equity Research
Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.
Compared to Estimates, Labcorp (LH) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Labcorp (LH) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Labcorp (LH) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Labcorp (LH) delivered earnings and revenue surprises of 4.23% and 0.78%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for These 4 MedTech Stocks in Q2 Earnings?
by Urmimala Biswas
Here is a sneak peek into how four MedTech companies, LH, BIO, TFX and BRKR, are expected to fare in their second-quarter results, slated to be released tomorrow.
Earnings Preview: Henry Schein (HSIC) Q2 Earnings Expected to Decline
by Zacks Equity Research
Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Labcorp (LH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Align Technology (ALGN) Q2 Earnings Top Estimates
by Zacks Equity Research
Align Technology (ALGN) delivered earnings and revenue surprises of 3.88% and 0.89%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's How Labcorp (LH) is Placed Ahead of Q2 Earnings Release
by Zacks Equity Research
Labcorp's (LH) second-quarter 2024 performance is expected to reflect the robust execution of strategic priorities and solid business performances.
Strength Seen in Henry Schein (HSIC): Can Its 5.4% Jump Turn into More Strength?
by Zacks Equity Research
Henry Schein (HSIC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Implied Volatility Surging for Labcorp (LH) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Labcorp (LH) stock based on the movements in the options market lately.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Labcorp (LH) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is It the Right Time to Hold Labcorp (LH) in Your Portfolio?
by Zacks Equity Research
Labcorp's (LH) concentrated development in high-growth areas and strategic partnerships appear encouraging.
Why Labcorp (LH) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Labcorp (LH) to Assess Preeclampsia Risk With New Test
by Zacks Equity Research
Labcorp's (LH) new first-trimester test is the latest addition to its dedication to improving women's health.
Here's Why Investors Should Retain Labcorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about Labcorp (LH), led by strategic acquisitions and strong expansion in the Biopharma Laboratory.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.